drug
lotilaner
Marketedupdated 3mo agoby $TARS Tarsus Pharmaceuticals, Inc.
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for nasopharyngeal carcinoma and eye infection and 2 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying lotilaner
- phase2A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
- phase2Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)
- phase4Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers
- phase3Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study
- phase1A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects
- phase2Study of TP-04 in Participants With Papulopustular Rosacea
- phase1Study to Evaluate the Food Effect of TP-05 in Healthy Participants
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 24, 2028
~1.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (9)
- Dec 14, 2038method-of-use (U-3674)US 10835517
- Dec 14, 2038method-of-use (U-3674)US 11197847
- Dec 14, 2038method-of-use (U-3674)US 11690826
- Dec 14, 2038method-of-use (U-3674)US 11690827
- Dec 14, 2038formulationUS 11752137
- Dec 14, 2038method-of-use (U-3674)US 12171750
- Dec 14, 2038formulationUS 12213964
- Dec 14, 2038formulationUS 12364685
- Jan 17, 2030compositionUS 83836593.4y
FDA exclusivities (1)
- Jul 24, 2028NCENew Chemical Entity (5y)1.9y
News(1)
- Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drugTarsus Pharmaceuticals is fronting $450 million to acquire Alkeus Pharmaceuticals for its phase 3-stage retinal disease therapy that's being touted as a potential blockbuster.fiercebiotech · 9d ago
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that